XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.4
Debt (Additional Information) (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 21, 2024
Oct. 08, 2024
Sep. 23, 2024
Sep. 17, 2024
Jul. 16, 2024
Jun. 30, 2024
Jun. 11, 2024
Sep. 21, 2023
Jul. 01, 2023
Jun. 27, 2023
Apr. 30, 2023
Mar. 21, 2023
Sep. 30, 2023
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Oct. 07, 2024
Sep. 20, 2024
Jun. 18, 2024
Dec. 31, 2023
Oct. 11, 2023
Debt Instrument [Line Items]                                            
Principle amount of issued debt                     $ 25,000,000                      
Net cash proceeds for direct offering                               $ 7,000,000            
Repayment of debt prinnciple installment                               $ 36,700,000 $ 0          
Loan             $ 100,000,000                              
Company Receives The FSF Deposit Period             70 days                              
Non-Refundable Deposit Amount             $ 10,000,000                              
Ordinary shares issued             3,250,000             191,790,520   191,790,520       3,250,000 160,084,250  
Deposit Warrant         $ 1.2   $ 1.2                              
Repurchase of warrants                           $ 298,000   $ 300,000 $ 0          
Warrant Purchase                           250,000   250,000            
Warrant Exercise Price         $ 1.2   $ 1.2                              
Commitment Amount             $ 85,000,000                              
Endeavor for Liquidated Damages                               $ 20,000,000            
Debt Instrument Redemption                               The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days’ prior written notice to Yorkville (the “Redemption Notice”), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.            
Fair Value of the Fee Warrant                               $ 300,000            
Common stock, shares issued             3,250,000             191,790,520   191,790,520       3,250,000 160,084,250  
FSB Deposit                           $ 14,700,000   $ 14,700,000            
Interest expense                           100,000   100,000            
Maximum [Member]                                            
Debt Instrument [Line Items]                                            
Common stock at a conversion price                                           $ 2
Minimum [Member]                                            
Debt Instrument [Line Items]                                            
Common stock at a conversion price                                           $ 0.5
Oramed Note [Member]                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt           $ 10,000,000             $ 101,900,000                  
Net cash proceeds for direct offering                               9,578,835            
Estimated fair value                           69,900,000   $ 69,900,000            
Debt maturity date   Sep. 23, 2024                                        
Maturity Date   Sep. 23, 2024                                        
Senior Secured Convertible Notes [Member]                                            
Debt Instrument [Line Items]                                            
Debt Instrument, Periodic Payment   $ 12,500,000,000                                        
Securities Purchase Agreement                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt                       $ 25,000,000                    
Debt instrument, description                               The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0 million upon the signing of the Yorkville SPA, which was funded on March 21, 2023, (ii) $7.5 million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the “Securities Act”), which was funded on April 11, 2023 and (iii) $7.5 million at the time such registration statement is declared effective by the SEC, which was funded on April 20, 2023.            
Debt instrument, interest rate                       7.00%                    
Debt maturity date                       Dec. 21, 2023       Mar. 15, 2024            
Common stock at a conversion price                       $ 8                    
Debt Instrument Principal Amount, Percentage                       5.00%                    
Debt payment terms                               The Company had the option to repay either (i) in cash, with premium equal to 5% in respect of the principal amount of such payment, or (ii) by submitting a notice for an advance under the A&R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i) or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.            
Convertible Debentures Issued Percent                       96.00%                    
Redemption Premium                               10.00%            
Maturity Date                       Dec. 21, 2023       Mar. 15, 2024            
Securities Purchase Agreement | First installment [Member]                                            
Debt Instrument [Line Items]                                            
Repayment of debt prinnciple installment               $ 5,000,000                            
Securities Purchase Agreement | Second Installment [Member]                                            
Debt Instrument [Line Items]                                            
Repayment of debt prinnciple installment               15,000,000                            
Securities Purchase Agreement | Third Installment [Member]                                            
Debt Instrument [Line Items]                                            
Repayment of debt prinnciple installment               20,000,000                            
Securities Purchase Agreement | Oramed Note [Member]                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt               101,900,000                            
Debt instrument, description                             Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) the greater of (x) 4% and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March 21, 2024, an exit fee of approximately $3.1 million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i) Term SOFR plus 15% or (ii) the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April 1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).              
Estimated fair value                           $ 69,900,000   $ 69,900,000            
Debt Repayment Exit Fee               $ 3,100,000                            
Debt instrument, interest rate               4.00%                            
Debt maturity date               Mar. 21, 2025                            
Debt instrument, owned, percentage               50.00%                            
Debt instrument, default interest rate               15.00%                            
Debt instrument, percentage of interest accrued on principal amount               50.00%                            
Debt repayment, percentage of mandatory default rate of principal amount               125.00%                            
Debt repayment, percentage of mandatory default rate of accrued and unpaid interest               100.00%                            
Percentage of usage of cash proceeds from cash sweep financing               70.00%                            
Maturity Date               Mar. 21, 2025                            
Securities Purchase Agreement | Oramed Note [Member] | Monthly Basis [Member]                                            
Debt Instrument [Line Items]                                            
Debt instrument, interest rate               8.50%                            
Securities Purchase Agreement | Oramed Note [Member] | First installment [Member]                                            
Debt Instrument [Line Items]                                            
Debt maturity date               Mar. 21, 2025                            
Maturity Date               Mar. 21, 2025                            
Securities Purchase Agreement | Oramed Note [Member] | Second Installment [Member]                                            
Debt Instrument [Line Items]                                            
Debt maturity date               Dec. 21, 2023                            
Maturity Date               Dec. 21, 2023                            
Securities Purchase Agreement | Oramed Note [Member] | Third Installment [Member]                                            
Debt Instrument [Line Items]                                            
Debt maturity date               Mar. 21, 2024                            
Maturity Date               Mar. 21, 2024                            
Securities Purchase Agreement | Oramed Note [Member] | Fourth Installment [Member]                                            
Debt Instrument [Line Items]                                            
Debt maturity date               Jun. 21, 2024                            
Maturity Date               Jun. 21, 2024                            
Securities Purchase Agreement | Oramed Note [Member] | Five Installment [Member]                                            
Debt Instrument [Line Items]                                            
Debt maturity date               Sep. 21, 2024                            
Maturity Date               Sep. 21, 2024                            
Securities Purchase Agreement | Oramed Note [Member] | Six Installment [Member]                                            
Debt Instrument [Line Items]                                            
Debt maturity date               Dec. 21, 2024                            
Maturity Date               Dec. 21, 2024                            
Satisfaction Agreement [Member]                                            
Debt Instrument [Line Items]                                            
Related Party Transaction, Amounts of Transaction       $ 13,200,000                       $ 13,200,000            
Tranche One | Securities Purchase Agreement                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt                       $ 10,000,000                    
Tranche Two | Securities Purchase Agreement                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt                       7,500,000                    
Tranche Three | Securities Purchase Agreement                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt                       $ 7,500,000                    
Subsequent Event [Member] | Oramed Note [Member]                                            
Debt Instrument [Line Items]                                            
Repayment of debt prinnciple installment $ 15,000,000,000                                          
Subsequent Event [Member] | Securities Purchase Agreement | Senior Secured Convertible Notes [Member]                                            
Debt Instrument [Line Items]                                            
Common stock at a conversion price                                   $ 1.09        
A&R Yorkville Purchase Agreement                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt                     15,000,000                      
Net cash proceeds                     $ 14,400,000                      
Ordinary shares issued                           632,431   632,431            
Convertible Debentures Repaid                               $ 4,400,000            
Common Stock at a conversion price                               $ 8            
Outstanding debt instrument                               $ 7,700,000            
Change in fair value                           $ 35,000   35,000            
Outstanding principal amount                           $ 5,000,000   $ 5,000,000            
Common stock, shares issued                           632,431   632,431            
Oramed Letter Agreement | Oramed Note [Member]                                            
Debt Instrument [Line Items]                                            
Repurchase of warrants     $ 300,000                                      
Warrant Purchase     4,000,000                                      
Date of Maturity Start                               Sep. 23, 2024            
Maturity Date End                               Sep. 30, 2024            
Debt maturity date     Mar. 21, 2025                                      
Amortization payment     $ 1,700,000                                      
Payment to Oramed                                     $ 2,000,000      
Maturity Date     Mar. 21, 2025                                      
Oramed Letter Agreement | Oramed Note [Member] | Maximum [Member]                                            
Debt Instrument [Line Items]                                            
Amortization payment                               $ 20,000,000            
Oramed Letter Agreement | Oramed Note [Member] | Minimum [Member]                                            
Debt Instrument [Line Items]                                            
Amortization payment                               0            
Initial Closing [Member]                                            
Debt Instrument [Line Items]                                            
Company Receives The FSF Deposit Period             60 days                              
Non-Refundable Deposit Amount             $ 85,000,000                              
Warrant Purchase             24,375,000                              
Company receives the FSF Deposit             $ 15,000,000                              
Second Closing [Member]                                            
Debt Instrument [Line Items]                                            
Warrant Purchase             4,875,000                              
Revolving Credit Facility [Member]                                            
Debt Instrument [Line Items]                                            
Principle amount of issued debt                               $ 75,000,000            
Termination fees                           0.50%   0.50%            
Facility cap maximum                   95.00%                        
Facility cap minimum                   85.00%                        
Outstanding debt instrument                   $ 250,000                        
Cash on hand                           $ 1,000,000   $ 1,000,000            
Outstanding principal amount                           $ 14,300,000   $ 14,300,000         $ 17,000,000  
Accounts receivable revolving loan facility in an aggregate amount               $ 30,000,000   $ 30,000,000                        
Line Of Credit Facility Interest Rate                 1.50%